Koh Eitetsu, Iizasa Toshihiko, Yamaji Haruko, Sekine Yasuo, Hiroshima Kenzo, Yoshino Ichiro, Fujisawa Takehiko
Department of Thoracic Surgery, Tokyo Women's Medical University Yachiyo Medical Center, Owada-Shinden Yachiyo City, Chiba, Japan.
Int J Surg Pathol. 2012 Jun;20(3):233-9. doi: 10.1177/1066896911436274. Epub 2012 Feb 13.
The aims of the study were to identify the significance of interleukin (IL)-6 production and to determine whether IL-6 production influences long-term survival in patients with non-small-cell lung cancer (NSCLC).
A series of 90 patients with NSCLC who underwent surgery between 2005 and 2007 was analyzed. Preoperative serum IL-6 was measured, and tumor samples were immunohistochemically stained for IL-6.
Serum IL-6 levels were elevated in 43 of 90 cases (47.7%), and 23 (25.5%) of 90 cases stained positively for IL-6 (P = .00265). The prognosis of patients with NSCLC who had positive immunohistochemical staining was significantly worse than that for those who had negative staining, by univariate analysis (P = .0027). Multivariate analysis indicated that tumor size, postoperative stage, and overexpression of IL-6 were independent prognostic factors.
The expression of IL-6 in tumor correlated with the concentration of serum IL-6, tumor progression, and overall survival in patients with NSCLC.
本研究的目的是确定白细胞介素（IL）-6产生的意义，并确定IL-6的产生是否影响非小细胞肺癌（NSCLC）患者的长期生存。
分析了2005年至2007年间接受手术的90例NSCLC患者。测量术前血清IL-6，并对肿瘤样本进行IL-6免疫组化染色。
90例中有43例（47.7%）血清IL-6水平升高，90例中有23例（25.5%）IL-6免疫组化染色呈阳性（P = 0.00265）。单因素分析显示，免疫组化染色阳性的NSCLC患者预后明显差于染色阴性患者（P = 0.0027）。多因素分析表明，肿瘤大小、术后分期和IL-6过表达是独立的预后因素。
NSCLC患者肿瘤中IL-6的表达与血清IL-6浓度、肿瘤进展和总生存相关。
